Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX6018 in healthy subjects
NCT06310746Phase 1Completed
- Sponsor
- Henlius
- Start
- Apr 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing HLX6018 with Placebo (2 arms). Primary endpoints: Adverse Events at 99 days and Serious Adverse Events at 99 days. Started Apr 2024; status: completed.
02
Drugs
HLX6018
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06310746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310746.